Allergic Rhinitis Treatment Market to Surpass US$ 20,595.6 Million by 2030, Says Coherent Market Insights (CMI)

Allergic Rhinitis Treatment Market: Expanding Opportunities for Nasal Allergy Relief Solutions

/EIN News/ -- Burlingame, March 03, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global allergic rhinitis treatment market is estimated to be valued at US$ 14,916.9 million in 2022 and is expected to exhibit a CAGR of 4.1% during the forecast period (2022-2030).

Key Trends and Analysis of the Global Allergic Rhinitis Treatment Market:

Major players operating in the market are focusing on adopting strategies such as collaboration, which is expected to drive the market growth over the forecast period. For instance, in January 2022, Stallergenes Greer, one of the global healthcare companies specializing in allergen immunotherapy (AIT), announced that it had entered into a research collaboration with Imperial College London, one of the world's leading universities, to discover biomarkers of allergen immunotherapy (AIT) to address the needs of patients with allergies.

Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/1201

Allergic Rhinitis Treatment Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 14,916.9 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	4.1%	2030 Value Projection:	US$ 20,595.6 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Treatment Type: Immunotherapy (SCIT, SLITD, SLITT), Anti-histamines, Decongestants, Leukotriene Receptor Antagonists, Corticosteroids By Route of Administration: Oral, Nasal, Intraocular, Intravenous By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, E-commerce
Companies covered:	Merck & Co., Inc., Boehringer Ingelheim International GmbH, AstraZeneca, GSK plc., Johnson & Johnson Services, Inc. Teva Pharmaceutical Industries Ltd., Novartis AG, Mylan N.V., Aytu BioPharma, Inc., Glenmark Pharmaceuticals Ltd, Himalaya Wellness Company, Regeneron Pharmaceuticals Inc., Allergy Therapeutics, Stallergenes Greer, Bayer AG, Dr. Reddy’s Laboratories Ltd, ALK-Abelló A/S, and Revolo Biotherapeutics
Growth Drivers:	Increasing prevalence of allergic rhinitis and increasing research and development activities like clinical trials
Restraints & Challenges:	Termination of ongoing clinical trials

Key Market Takeaways:

The global allergic rhinitis treatment market is expected to exhibit a CAGR of 4.1% during the forecast period due to increasing product approval by different regulatory authorities such as U.S. Food and Drug Administration or The European Commission. This is expected to fuel demand for allergic rhinitis treatment and drive the market growth over the forecast period. For instance, in June 2019, ALK-Abelló A/S, a pharmaceutical company, announced that it had completed the marketing authorization procedure for ITULAZAX, a tree sublingual allergy immunotherapy (SLIT) tablet in 17 European countries. ITULAZAX is indicated in adult patients for the treatment of moderate-to-severe allergic rhinitis and/or conjunctivitis.

Among Distribution Channel, the Retail Pharmacies segment is estimated to hold a dominant position in the global allergic rhinitis treatment market over the forecast period, owing to the guideline-compliant advice provided by pharmacy assistants for allergic rhinitis. For instance, in December 2021, a research article published by ScienceDirect, according to which, most pharmacies provided appropriate advice for a condition-based request for allergic rhinitis.

Among region, North America is expected to hold a dominant position over the forecast period, owing to the increasing the U.S. Food and Drug Administration approval for a nasal antihistamine. For instance, in June 2021, the U.S. Food and Drug Administration, a federal agency that belongs to the U.S. Department of Health and Human Services, announced the approval of Astepro (azelastine hydrochloride), a nasal antihistamine, indicated for seasonal and perennial allergic rhinitis manufactured by Bayer AG, a pharmaceutical and biotechnology company.

Competitive Landscape:

Key players operating in the global allergic rhinitis treatment include Merck & Co., Inc., Boehringer Ingelheim International GmbH, AstraZeneca, GSK plc., Johnson & Johnson Services, Inc. Teva Pharmaceutical Industries Ltd., Novartis AG, Mylan N.V., Aytu BioPharma, Inc., Glenmark Pharmaceuticals Ltd, Himalaya Wellness Company, Regeneron Pharmaceuticals Inc., Allergy Therapeutics, Stallergenes Greer, Bayer AG, Dr. Reddy’s Laboratories Ltd, ALK-Abelló A/S, Revolo Biotherapeutics among other prominent players

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1201

Market Segmentation:

Global Allergic Rhinitis Treatment Market, By Treatment Type:
- Immunotherapy
  - SCIT
  - SLITD
  - SLITT
- Anti-histamines
- Decongestants
- Leukotriene Receptor Antagonists
- Corticosteroids
Global Allergic Rhinitis Treatment Market, By Route of Administration:
- Oral
- Nasal
- Intraocular
- Intravenous
Global Allergic Rhinitis Treatment Market, By Distribution Channel:
- Retail Pharmacies
- Hospital Pharmacies
- E-commerce
Global Allergic Rhinitis Treatment Market, By Region:
- North America
  - By Country
    - U.S.
    - Canada
- Latin America
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Country
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Country
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Country
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Region/Country
    - South Africa
    - Central Africa
    - North Africa

Related Market Intelligence Reports:

India Immuno -Oncology Drugs Market, by Drug Type (Immune Checkpoint Inhibitors (Nivolumab, Atezolimumab, Pembrolizumab, Durvalumab), Monoclonal Antibodies (Rituximab, Trastazumab, Bevacizumab , Nimotuzumab, Pertuzumab, Ado-Trastuzumab Emtansine ), and Cancer Vaccines (Gardasil, Cervarix), by Cancer Type (Lung Cancer, Blood Cancer, Breast Cancer, Ovarian Cancer, Cervical Cancer, Colorectal Cancer, Stomach Cancer, Head & Neck Cancer, and Others), and by Distribution Channel (Online Pharmacies, Retail Pharmacies, and Hospital Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2022 – 2028

Digestive Drugs Market, By Type (Branded and Generic), By Drug Class (5-aminosalicylates, GI stimulants, Laxatives, Antacids, H2 Antagonists, Antidiarrheals, Others), By Route of Administration (Oral, Intravenous, Others), By Application (Gastroesophageal Reflux Disease (GERD), Irritable Bowel Syndrome, Ulcerative Colitis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Follow Us: LinkedIn | Twitter

Mr. Shah
                    Senior Client Partner – Business Development
                    Coherent Market Insights
                    
                    Phone:
                    US: +1-206-701-6702
                    UK: +44-020-8133-4027
                    Japan: +81-050-5539-1737
                    India: +91-848-285-0837
                    Email: sales@coherentmarketinsights.com
                    Website: https://www.coherentmarketinsights.com

Distribution channels: Banking, Finance & Investment Industry, Business & Economy, Science

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Submit your press release